WallStSmart

Insmed Inc (INSM)vsBiomotion Sciences Ordinary Shares (SLXN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

SLXN leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

SLXN

Avoid

23

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for INSM.

SLXNUndervalued (+99.9%)

Margin of Safety

+99.9%

Fair Value

$2373.81

Current Price

$1.34

$2372.47 discount

UndervaluedFair: $2373.81Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

SLXN1 strengths · Avg: 10.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

SLXN4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.20M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : SLXN

The strongest argument for SLXN centers on Price/Book.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : SLXN

The primary concerns for SLXN are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while SLXN is a value play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

SLXN generates stronger free cash flow (-3M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 23/100). SLXN offers better value entry with a 99.9% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Biomotion Sciences Ordinary Shares

HEALTHCARE · BIOTECHNOLOGY · USA

Biomotion Sciences (SLXN) is an innovative biotechnology firm at the forefront of developing transformative therapies aimed at tackling severe and complex medical conditions. Specializing in regenerative medicine, the company boasts a promising pipeline of product candidates designed to enhance patient outcomes significantly. Backed by strategic collaborations that strengthen its research and development initiatives, Biomotion Sciences is positioned to capitalize on the growing demand for effective therapeutic solutions, making it a compelling investment opportunity in the dynamic biotechnology sector.

Want to dig deeper into these stocks?